<DOC>
	<DOCNO>NCT00250120</DOCNO>
	<brief_summary>To determine overall response rate liposomal 9-Nitro-20 ( S ) -Camptothecin ( L9NC ) administer aerosolization patient non-small-cell lung cancer ( stage ) . To determine toxicity profile L9NC administer aerosolization 5 consecutive day per week X 8 week , every 10 week . To perform pharmacology study L9NC plasma , lung aerosolization . A specific protocol write part .</brief_summary>
	<brief_title>Pharmacology Study Aerosolized Liposomal</brief_title>
	<detailed_description>This single-arm , non-randomized Phase II trial DLPC-9NC administer aerosol 5 consecutive day per week 8 week every 10 week . Dose : 0.4 mg/ml 9-NC aerosol reservoir 60 minute ( = daily dose 0.52 mg/m2/day ) per day X5 every week , X8 week , observe 2 week . One course = 10 week . Patients resectable lung cancer receive one course treatment operate two week complete 8-week course .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Rubitecan</mesh_term>
	<criteria>Patients participate INST 1402C protocol Phase II Study Aerosolized LiposomalNitro20 ( S ) Camptothecin ( L9NC ) Patients Advanced ( NSCLC ) Lung Cancer eligible tumor resectable curative intent determine Dr. Reza Mehran .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>L9NC</keyword>
	<keyword>Aerosolized Liposomal 9-Nitro-20 ( S ) -Camptothecin</keyword>
</DOC>